Calcineurin inhibitor nephrotoxicity: Longitudinal assessmment by protocol histology

Transplantation

Volumn 78, Issue 4, 2004, Pages 557-565

  Nankivell, Brian J ^a,c   Borrows, Richard J ^a,b   Fung, Caroline L S ^c   O'Connell, Philip J ^a   Chapman, Jeremy R ^a   Allen, Richard D M ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ST MARY S HOSPITAL   (United Kingdom)

^c WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; ALLOGRAFT; ARTERY HYALINOSIS; ARTICLE; CLINICAL PROTOCOL; DIALYSIS; DISEASE MARKER; DOSE RESPONSE; FEMALE; GRAFT FAILURE; HISTOLOGY; HUMAN; HUMAN TISSUE; HYALINE DEGENERATION; IMMUNOSUPPRESSIVE TREATMENT; KAPLAN MEIER METHOD; KIDNEY BIOPSY; KIDNEY CALCIFICATION; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LONG TERM CARE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; STRIPED FIBROSIS; TUBULAR MICROCALCIFICATION;

ADULT; ARTERIOLES; CALCINEURIN; CYCLOSPORINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 4143127834     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000128636.70499.6E     Document Type: Article

References (33)

1. Myers BD, Newton L. Cyclosporine-induced chronic nephropathy: An obliterative microvascular renal injury. J Am Soc Nephrol 1991; 2(2 suppl 1): S45.
2. Bertani T, Ferrazzi P, Schieppati A, et al. Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients. Kidney Int 1991; 40(2): 243.
3. Bennett WM, DeMattos A, Meyer MM, et al. Chronic cyclosporine nephropathy: The Achilles' heel of immunosuppressive therapy. Kidney Int 1996; 50(4): 1089.
4. MacPhee IA, Bradley JA, Briggs JD, et al. Long-term outcome of a prospective randomized trial of conversion from cyclosporine to azathioprine treatment one year after renal transplantation. Transplantation 1998; 66(9): 1186.
5. European multicentre trial of cyclosporine in renal transplantation: 10-year follow-up. Transplant Proc 1993; 25 (1 pt 1): 527.
6. Nankivell BJ, Borrows RJ, Fung CL-S, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349(24): 2326.
7. Matas AJ, Almond PS, Moss A, et al. Effect of cyclosporine on renal function in kidney transplant recipients: A 12-year follow-up. Clin Transplant 1995; 9(6): 450.
8. Lewis RM. Long-term use of cyclosporine A does not adversely impact on clinical outcomes following renal transplantation. Kidney Int Suppl 1995; 52: S75.
9. Solez K, Vincenti F, Filo RS. Histopathologic findings from 2-year protocol biopsies from a U. S. multicenter kidney transplant trial comparing tacrolimus versus cyclosporine: A report of the FK506 Kidney Transplant Study Group. Transplantation 1998; 66(12): 1736.
10. Weir MR. Methods and outcomes of calcineurin inhibitor reduction or withdrawal in patients with chronic allograft nephropathy after the first year posttransplantation. Transplant Proc 2001; 33(4 suppl): 19S.
11. Morozumi K, Thiel G, Albert FW, et al. Studies on morphological outcome of cyclosporine-associated arteriolopathy after discontinuation of cyclosporine in renal allografts. Clin Nephrol 1992; 38(1): 1.
12. Solez K, Axelsen RA, Benediktsson H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology. Kidney Int 1993; 44(2): 411.
13. Antonovych TT, Sabnis SG, Austin HA, et al. Cyclosporine A-induced arteriolopathy. Transplant Proc 1988; 20(3 suppl 3): 951.
14. Benigni A, Bruzzi I, Mister M, et al. Nature and mediators of renal lesions in kidney transplant patients given cyclosporine for more than one year. Kidney Int 1999; 55(2): 674.
15. Mihatsch MJ, Thiel G, Ryffel B. Histopathology of cyclosporine nephrotoxicity. Transplant Proc 1988; 20(3 suppl 3): 759.
16. Mihatsch MJ, Ryffel B, Gudat F. The differential diagnosis between rejection and cyclosporine toxicity. Kidney Int Suppl 1995; 52: S63.
17. Cosio FG, Pelletier RP, Sedmak DD, et al. Pathologic classification of chronic allograft nephropathy: Pathogenic and prognostic implications. Transplantation 1999; 67(5): 690.
18. Davies DR, Bittmann I, Pardo J. Histopathology of calcineurin inhibitor-induced nephrotoxicity. Transplantation 2000; 69(12 suppl): SS11.
19. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55(2): 713.
20. Nankivell BJ, Fenton-Lee CA, Kuypers DR, et al. Effect of histological damage on long-term kidney transplant outcome. Transplantation 2001; 71(4): 515.
21. Falkenhain ME, Cosio FG, Sedmak DD. Progressive histologic injury in kidneys from heart and liver transplant recipients receiving cyclosporine. Transplantation 1996; 62(3): 364.
22. Azuma H, Nadeau K, Mackenzie HS, et al. Nephron mass modulates the hemodynamic, cellular, and molecular response of the rat renal allograft. Transplantation 1997; 63(4): 519.
23. Lipkowitz GS, Madden RL, Mulhern J, et al. Long-term maintenance of therapeutic cyclosporine levels leads to optimal graft survival without evidence of chronic nephrotoxicity. Transplant Int 1999; 12(3): 202.
24. Ojo BM, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a non-renal organ. N Engl J Med 2003; 349(10): 931.
25. Powles AV, Cook T, Hulme B, et al. Renal function and biopsy findings after 5 years' treatment with low-dose cyclosporin for psoriasis. Br J Dermatol 1993; 128(2): 159.
26. Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342(9): 605.
27. Helderman JH, Van Buren DH, Amend WJJ, et al. Chronic immunosuppression of the renal transplant patient. J Am Soc Nephrol 1994; 4(8 suppl): s2.
28. Franceschini N, Alpers CE, Bennett WM, et al. Cyclosporine arteriolopathy: Effects of drug withdrawal. Am J Kidney Dis 1998; 32(2): 247.
29. Sandborn WJ, Hay JE, Porayko MK, et al. Cyclosporine withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejection. Hepatology 1994; 19(4): 925.
30. Halloran PF, Melk A, Barth C. Rethinking chronic allograft nephropathy: The concept of accelerated senescence. J Am Soc Nephrol 1999; 10(1): 167.
31. Morath C, Zeier M. Review of the antiproliferative properties of mycophenolate mofetil in non-immune cells. Int J Clin Pharmacol Ther 2003; 41(10): 465.
32. Shihab FS, Bennett WM, Yi H, et al. Mycophenolate mofetil ameliorates arteriolopathy and decreases transforming growth factor-beta1 in chronic cyclosporine nephrotoxicity. Am J Transplant 2003; 3(12): 1550.
33. Dell'Antonio G, Randhawa PS. "Striped" pattern of medullary ray fibrosis in allograft biopsies from kidney transplant recipients maintained on tacrolimus. Transplantation 1999; 67(3): 484.